Evidence map›Paper›PMID 37606897›Full record

ArticleJournal of comparative effectiveness research2023

Cost-consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada.

Virender Bhan, Fraser Clift, Moogeh Baharnoori, Kimberly Thomas, Barkha P Patel, François Blanchette, Nicholas Adlard, Umakanth Vudumula, Kapil Gudala, Nikkita Dutta and 3 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of comparative effectiveness research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Observational
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 4 countries.

Virender BhanDepartment of Medicine, The University of British Columbia, Vancouver, BC, V6T 2B5, Canada.
Fraser CliftDepartment of Neurology, Memorial University of Newfoundland, St. John's, NL, A1B 3V6, Canada.
Moogeh BaharnooriDepartment of Medicine, Division of Neurology, Queen's University, Kingston, ON, K7L 3N6, Canada.
Kimberly ThomasEVERSANA, Burlington, ON, L7N 3H8, Canada.
Barkha P PatelEVERSANA, Burlington, ON, L7N 3H8, Canada.
François BlanchetteNovartis Canada Inc., Dorval, QC, H9S 1A9, Canada.
Nicholas AdlardNovartis Pharma AG, Basel,4056, Switzerland.
Umakanth VudumulaNovartis Ireland Limited, Dublin, D04 NN12, Ireland.
Kapil GudalaNovartis Healthcare Pvt. Ltd., Hyderabad, 500081, India.
Nikkita DuttaEVERSANA, Burlington, ON, L7N 3H8, Canada.
Daniel GrimaEVERSANA, Burlington, ON, L7N 3H8, Canada.
Soukaïna MouallifNovartis Canada Inc., Dorval, QC, H9S 1A9, Canada.
Fatine FarhaneNovartis Canada Inc., Dorval, QC, H9S 1A9, Canada.
EVERSANA (Canada) · CANovartis (Canada) · CAMemorial University of Newfoundland · CANovartis (India) · INNovartis (Ireland) · IENovartis (Switzerland) · CHQueen's University · CAUniversity of British Columbia · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingAntibodies, Monoclonal, HumanizedCanadaDisease ProgressionHumansNatalizumabAntibodies, Monoclonal, HumanizedNatalizumabofatumumabCanadacost-consequencedisease-modifying therapymultiple sclerosisofatumumab

Identifiers

PMID37606897
PMCPMC10690431
OpenAlexW4386046576

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.